abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial (clinicaltrials.gov)

P3, N=1524, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026

3 days ago

Enrollment open • Trial initiation date

FOLH1 positive

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function (clinicaltrials.gov)

P2, N=23, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

4 days ago

Enrollment closed • Trial completion date • Trial primary completion date

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Natural Flavonoids Genistein and Baicalein as Well-Tolerated Radiosensitizers to Enhance the Efficacy of 177Lu-PSMA617 in Prostate Cancer: In Vitro and In Vivo Studies. (PubMed, Research (Wash D C))

Their natural origin and established safety profile underscore their translational potential. Thus, genistein and baicalein represent promising novel adjuvants for prostate cancer radioligand therapy.

7 days ago

Preclinical • Journal

CASP3 (Caspase 3)

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)

P1, N=42, Recruiting, Weill Medical College of Cornell University | N=20 --> 42 | Active, not recruiting --> Recruiting

7 days ago

Enrollment open • Enrollment change

CELLSEARCH®

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. (PubMed, Eur J Nucl Med Mol Imaging)

In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.

8 days ago

Journal

FOLH1 (Folate hydrolase 1) • ARSI (Arylsulfatase Family Member I)

FOLH1 expression

enzalutamide • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy. (PubMed, ACS Nano)

In a head-to-head comparison with clinically approved 177Lu-PSMA-617 (Pluvicto), PSMA-targeted TRT@LnOMVs achieved a 90% survival rate in a prostate cancer model, far surpassing the 25% survival rate of Pluvicto...This occurred through reprogramming immunosuppressive myeloid compartments (including neutrophil subsets and macrophages), expanding cytotoxic CD8+ T and NK cell infiltration, and activating innate immunity to trigger robust antitumor responses. Collectively, TRT@LnOMVs represent a versatile class of biohybrid therapeutics, offering a robust paradigm for next-generation radio-immunotherapy.

9 days ago

Journal

CD8 (cluster of differentiation 8)

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

11d

CaboLu: Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P1, N=33, Suspended, University of Utah | Trial completion date: May 2028 --> Dec 2028 | Recruiting --> Suspended | Trial primary completion date: May 2026 --> Dec 2026

11 days ago

Trial completion date • Trial suspension • Trial primary completion date

FOLH1 positive

Cabometyx (cabozantinib tablet) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

11d

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC (clinicaltrials.gov)

P2, N=62, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

11 days ago

Trial completion

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

14d

RENALUT: Radiopharmaceutical Treatment of Advanced Kidney Cancer (clinicaltrials.gov)

P2, N=48, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting

14 days ago

Enrollment open

FOLH1 positive

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • lutetium zadavotide guraxetan (PNT2002)

15d

PLUVIPAC: Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP) (clinicaltrials.gov)

P=N/A, N=107, Completed, Central Hospital, Nancy, France | Recruiting --> Completed

15 days ago

Trial completion

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

16d

ZENITH: Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=30, Not yet recruiting, Stuthi Perimbeti

16 days ago

New P2 trial

BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)

BRCA mutation

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • zanzalintinib (XL092)